ClinicalTrials.gg
Not yet recruitingNCT07858812Updated Nov 12, 2026

Validity and Reliability of the Turkish Version of the Revised Bath CRPS Body Perception Disturbance Scale

An observational study in Complex Regional Pain Syndrome (CRPS), sponsored by Izmir Democracy University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Izmir Democracy University · Observational

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
42
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Complex Regional Pain Syndromes with a site in Turkey — 7 open to participants now, 7 under way, none of them phase 3. Complex Regional Pain Syndromes · Turkey.

Started
2026
with 2 others
Observational
4 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Izmir Democracy University

Among the 14 studies in Complex Regional Pain Syndromes with a site in Turkey, this one is one of 3 that started in 2026, is one of 4 observational ones, and was the 14th registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

7 of the 14 studies in Complex Regional Pain Syndromes with a site in Turkey are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 41 Complex Regional Pain Syndromes studies recruiting now, 19 (46%) set no upper age limit and 16 (39%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Complex Regional Pain Syndromes with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to perform the cross-cultural adaptation of the Revised Bath Complex Regional Pain Syndrome Body Perception Disturbance Scale (r-B-CRPS-BPDS) into Turkish and to evaluate the validity and reliability of the Turkish version in adults with Complex Regional Pain Syndrome (CRPS). Adult participants diagnosed with CRPS according to the Budapest clinical diagnostic criteria will be included. Participants will complete the Turkish r-B-CRPS-BPDS together with measures of kinesiophobia, health-related quality of life, and pain intensity. CRPS clinical severity will also be assessed. Construct validity, internal consistency, test-retest reliability, measurement error, and floor and ceiling effects of the Turkish r-B-CRPS-BPDS will be evaluated. For test-retest reliability, clinically stable participants will complete the r-B-CRPS-BPDS again after 7-10 days. The study is intended to provide a culturally adapted, valid, and reliable Turkish version of the r-B-CRPS-BPDS for assessing body perception disturbance in individuals with CRPS.

03

Conditions studied

  • Complex Regional Pain Syndrome (CRPS)

Keywords

  • complex regional pain syndrome
  • body image
  • psychometrics
  • validation study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will include patients aged 18 years and older who have been diagnosed with complex regional pain syndrome based on Budapest clinical diagnosis criteria and who have applied to the Physical Medicine and Rehabilitation Outpatient Clinic at İzmir Democracy University Buca Seyfi Demirsoy Education and Research Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the criteria for a diagnosis of CRPS based on the Budapest clinical diagnostic criteria following clinical evaluation
  • Have complex regional pain syndrome affecting the upper or lower extremity
  • Be able to provide written to participate in the study
  • Have the cognitive ability to understand the forms and scales in Turkish

Exclusion criteria

Exclusion Criteria:

  • The presence of cognitive impairment or communication difficulties severe enough to prevent understanding of the scales or providing reliable responses
  • The presence of a central neurological disorder that could significantly affect body perception, somatosensory function, or limb function (e.g., stroke, multiple sclerosis, spinal cord injury)
  • The presence of a serious additional neurological or musculoskeletal disorder in the evaluated extremity, other than CRPS, that could significantly affect body perception and function
  • The presence of a severe psychiatric disorder severe enough to prevent reliable clinical evaluation and administration of the scales
  • Inability to complete the scales or demonstrate sufficient cooperation during the data collection process.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
42 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    complex regional pain syndrome

06

What researchers measure

Primary outcomes

  1. Construct Validity of the Turkish Revised Bath Complex Regional Pain Syndrome Body Perception Disturbance Scale

    The construct validity of the Turkish version of the Revised Bath Complex Regional Pain Syndrome Body Perception Disturbance Scale (r-B-CRPS-BPDS) will be evaluated in adults with Complex Regional Pain Syndrome. The r-B-CRPS-BPDS assesses disturbances in body perception related to the affected limb, including feelings of ownership, awareness of limb position, emotional feelings toward the limb, perceived differences in size, temperature, pressure, and weight, desire for amputation, and mental representation of the affected limb. The total score ranges from 0 to 47, with higher scores indicating greater body perception disturbance. Construct validity will primarily be examined by assessing the association between the r-B-CRPS-BPDS total score and the Tampa Scale for Kinesiophobia total score. Associations with pain intensity, health-related quality of life, and clinical CRPS severity will also be examined.

    Time frame: Day 1

  2. Internal Consistency of the Turkish r-B-CRPS-BPDS

    The internal consistency of the Turkish r-B-CRPS-BPDS will be evaluated using Cronbach's alpha coefficient and corrected item-total correlations. The analysis will determine the degree to which the items of the Turkish version consistently assess the construct of body perception disturbance in individuals with Complex Regional Pain Syndrome.

    Time frame: Day 1

  3. Test-Retest Reliability of the Turkish r-B-CRPS-BPDS

    Test-retest reliability will be evaluated in clinically stable participants by administering the Turkish r-B-CRPS-BPDS twice, with an interval of 7-10 days. Reliability will be assessed using the intraclass correlation coefficient (ICC), based on a two-way random-effects model, single measurement, and absolute agreement \[ICC(2,1)\]. Measurement error will additionally be evaluated using the standard error of measurement (SEM) and smallest detectable change (SDC).

    Time frame: Baseline and 7-10 days after baseline

Secondary outcomes

  1. Tampa Scale for Kinesiophobia

    The Tampa Scale for Kinesiophobia (TSK) is a 17-item self-report questionnaire used to assess fear of movement and reinjury. Each item is rated on a 4-point Likert scale. Higher total scores indicate greater levels of kinesiophobia. The Turkish version of the scale has demonstrated validity and reliability. The TSK total score will be used primarily to examine the construct validity of the Turkish r-B-CRPS-BPDS.

    Time frame: Day 1

  2. EQ-5D-5L

    The EQ-5D-5L will be used to assess health-related quality of life. It evaluates five dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with five response levels for each dimension. Participants will also rate their current overall health using the EQ Visual Analogue Scale (EQ VAS), ranging from 0 to 100, with higher scores representing better self-rated health. EQ-5D-5L outcomes will be examined in relation to body perception disturbance.

    Time frame: Day 1

  3. Numeric Rating Scale for Pain

    Pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS) ranging from 0 to 10. A score of 0 represents no pain, whereas a score of 10 represents the worst imaginable pain. Higher scores indicate greater pain intensity. The NRS score will be examined in relation to the r-B-CRPS-BPDS total score.

    Time frame: Day 1

  4. Complex Regional Pain Syndrome Severity Score

    Clinical severity of Complex Regional Pain Syndrome will be assessed using the Complex Regional Pain Syndrome Severity Score (CSS). The 17-item score incorporates patient-reported symptoms and signs identified during clinical examination across sensory, vasomotor, sudomotor/edema, motor, and trophic domains. Each item is scored as absent or present, producing a total score ranging from 0 to 17. Higher scores indicate greater clinical severity of Complex Regional Pain Syndrome.

    Time frame: Day 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the data contain potentially identifiable sensitive clinical information, and sharing was not covered in the original informed consent provided to participants. Additionally, institutional and national data protection regulations limit the transfer of raw, de-identified individual-level data outside the research team.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Nov 15, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 2 updates
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: responsible party
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858812
Lead sponsor
Izmir Democracy University
Responsible party
Kadir Songur (Principal Investigator, Izmir Democracy University) — Principal investigator
First posted
Oct 5, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Kadir Songür, Assoc. Prof.
Contact
kadir.93@gmail.com
+905054529231

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion